Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11

Johannes Duell, MD, Dragana Slavkovic, PhD, Margarete Karg, Uwe Reusch, PhD, Florian Eisele, Jens-Peter Marschner, MD, Hermann Einsele, MD, Martin Treder, PhD, Max S. Topp, MD

Blood (2016) 128 (22): 4130.

https://doi.org/10.1182/blood.V128.22.4130.4130

Published: 2016

Journal Articles

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2747.

https://doi.org/10.1182/blood.V126.23.2747.2747

Published: 2015

Journal Articles

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Xing Zhao, Narendiran Rajasekaran, PhD, Uwe Reusch, PhD, Michael Weichel, Kristina Ellwanger, Jens-Peter Marschner, MD, Martin Treder, Holbrook Kohrt, MD

Blood (2015) 126 (23): 2763.

https://doi.org/10.1182/blood.V126.23.2763.2763

Published: 2015

Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert

Blood (2015) 125 (26): 4024–4031.

https://doi.org/10.1182/blood-2014-12-614636

Published: 2015

Journal Articles

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Achim Rothe, MD, Stephanie Sasse, MD, Max S. Topp, MD, Dennis A. Eichenauer, MD, Bastian von Tresckow, MD, Horst-Dieter Hummel, MD, Miroslav Ravic, MD PhD, Jens-Peter Marschner, MD, Andreas Engert, MD

Blood (2014) 124 (21): 1753.

https://doi.org/10.1182/blood.V124.21.1753.1753

Published: 2014

NARROW

Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Email alerts

ASH Publications

American Society of Hematology

Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb ® AFM11

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only